Immunology · Complement Factor I Deficiency

Beyond Infection: Managing Long-Term Risks

At a Glance

Complement Factor I deficiency is not limited to infections: an overactive complement system can affect the kidneys, eyes, and rarely other organs. Planned urine, blood-pressure, kidney-function, and eye checks help detect complications early.

While the most immediate concern in Complement Factor I (CFI) deficiency is infection, the same chronically overactive immune system can also cause inflammation and damage in other parts of the body. Because the complement system remains permanently active, it can eventually turn its attention toward the body’s own tissues, particularly the kidneys and the eyes ^[1]^[2].

These complications are not caused by bacteria, but by the body’s inability to stop its own protective responses from becoming destructive ^[3].

The Kidneys: aHUS and C3G

The kidneys are highly sensitive to complement activity. In a systematic review of small published cohorts, approximately 16% of people with complete CFI deficiency experienced kidney manifestations ^[1]. Two main conditions are most common:

Atypical Hemolytic Uremic Syndrome (aHUS): This is a medical emergency where small blood clots form in the blood vessels affecting multiple organs, particularly the kidneys ^[4]. It often presents with acute kidney injury (a sudden drop in kidney function), a low platelet count (the cells that help blood clot), and hemolytic anemia (the destruction of red blood cells) ^[5]^[6]. Symptoms can include reduced urine output, high blood pressure, and extreme fatigue ^[4].
C3 Glomerulopathy (C3G): This is a slower-moving condition where C3-dominant complement deposits get stuck in the kidney’s filtering units (the glomeruli) ^[7]^[3]. This causes inflammation that can lead to blood or protein in the urine (proteinuria) and has a highly variable progression; it may eventually lead to kidney failure in some patients over many years, though not all ^[8]^[3].

Diagnosis of these conditions requires laboratory evaluation and specialist assessment, not merely symptom monitoring.

The Eyes: Macular Degeneration

The link between CFI and the eyes is very specific. Variants in the CFI gene that result in lower levels of Factor I are strongly linked to Age-Related Macular Degeneration (AMD) later in life, though much of this evidence involves heterozygous susceptibility carriers rather than the complete deficiency syndrome ^[9]^[10].

In these cases, the uncontrolled complement system causes inflammation at the back of the eye, leading to the formation of drusen (small yellow deposits) and a thinning of the retina ^[11]^[9]. This can progress to geographic atrophy, a condition where areas of the retina “waste away,” causing permanent vision loss ^[12]^[13]. While this usually affects older adults, some patients with complete deficiency may show early signs of retinal changes. A baseline ophthalmic assessment is often reasonable, though the timing and frequency of eye exams are an individualized decision for your care team ^[11]^[14].

Other Systemic Inflammation

Because the complement system travels through the entire bloodstream, other organs can occasionally be affected, though these are reported as rare case associations rather than established routine complications:

Rheumatological Manifestations: In a systematic review of complete CFI deficiency, some patients have shown signs of rheumatological disease, such as vasculitis—an inflammation of the blood vessels ^[1]. This often appears as a specific type of skin rash called palpable purpura (raised purple spots) or joint pain ^[15]^[16].
Neurological Complications: Very rarely, isolated case reports note complement-associated inflammation in the brain or spinal cord. This can include conditions such as transverse myelitis (inflammation of the spinal cord) or acute disseminated encephalomyelitis (ADEM), which involves widespread brain inflammation ^[17]^[18]. Symptoms of these rare events include sudden changes in coordination, weakness, or altered mental status ^[19]^[20].

Understanding these risks allows you to work with your medical team to establish a baseline of health, ensuring that if these complications ever arise, they are caught and managed early.

Common questions in this guide

Can Complement Factor I deficiency affect the kidneys?

Yes. Overactive complement activity can contribute to atypical hemolytic uremic syndrome, which may cause sudden kidney injury, low platelets, and red blood cell destruction, or C3 glomerulopathy, which may cause blood or protein in the urine and a gradual decline in kidney function. These problems require medical evaluation rather than symptom monitoring alone.

What symptoms could signal a kidney emergency such as aHUS?

Reduced urine output, high blood pressure, and extreme fatigue can occur with aHUS. Blood tests may also show sudden kidney injury, a low platelet count, and destruction of red blood cells, so new or rapidly worsening symptoms need prompt medical assessment.

Should a person with complete CFI deficiency have an eye examination?

A baseline eye examination may be reasonable because some CFI-related changes can affect the retina, even when there are no vision symptoms. The appropriate timing and frequency of follow-up should be individualized by the care team.

Is Complement Factor I deficiency linked to macular degeneration?

Some CFI gene variants that lower Factor I levels are associated with age-related macular degeneration, particularly in people who carry one susceptibility variant. People with complete deficiency may show early retinal changes, but the risk and timing are not the same for everyone.

Could a persistent rash or joint pain be related to CFI deficiency?

Rare inflammatory complications reported with complete CFI deficiency include blood-vessel inflammation, which may cause raised purple skin spots, and joint pain. Persistent or unexplained symptoms should be discussed with a clinician so other causes can also be assessed.

What neurological changes should someone with CFI deficiency watch for?

Very rare reports describe inflammation involving the brain or spinal cord. Sudden changes in coordination, weakness, altered mental status, or new vision changes should receive prompt medical attention.

How is long-term kidney health monitored in CFI deficiency?

Monitoring may include blood pressure checks, urine testing for blood or protein, and blood tests that assess kidney function and related complement activity. The schedule should be tailored by the treating specialists, especially for a person with complete deficiency or new symptoms.

Get notified when new evidence is published on Immunodeficiency with factor I anomaly.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (20)

1
Complete Complement Factor I (CFI) deficiency: a systematic review of forty-nine patients including three novel cases.
Rajabi E, Kheirabadi MC, Olyaei NA, et al.
BMC immunology 2025; (26(1)):54 doi:10.1186/s12865-025-00739-y.
PMID: 40713518
2
Complement factor I: Regulatory nexus, driver of immunopathology, and therapeutic.
Hallam TM, Sharp SJ, Andreadi A, Kavanagh D
Immunobiology 2023; (228(5)):152410 doi:10.1016/j.imbio.2023.152410.
PMID: 37478687
3
C3 glomerulonephritis and thrombotic microangiopathy of renal allograft after pulmonary infection in a male with concomitant two complement factor I gene variations: a case report.
Wen J, Wang W, Xu F, et al.
BMC nephrology 2018; (19(1)):148 doi:10.1186/s12882-018-0952-z.
PMID: 29940891
4
[Hemolytic kidney failure and transient ischemic attack in a 32-year-old female].
Anders R, Grohmann M, Lindner TH, et al.
Der Internist 2016; (57(10)):1022-1028 doi:10.1007/s00108-016-0092-0.
PMID: 27357251
5
A novel missense mutation in complement factor I predisposes patients to atypical hemolytic uremic syndrome: a case report.
Wei X, Li J, Zhan X, et al.
Journal of medical case reports 2022; (16(1)):101 doi:10.1186/s13256-022-03312-y.
PMID: 35241161
6
Atypical hemolytic-uremic syndrome due to complement factor I mutation.
Almalki AH, Sadagah LF, Qureshi M, et al.
World journal of nephrology 2017; (6(6)):243-250 doi:10.5527/wjn.v6.i6.243.
PMID: 29226095
7
Anti-complement-factor H-associated glomerulopathies.
Durey MA, Sinha A, Togarsimalemath SK, Bagga A
Nature reviews. Nephrology 2016; (12(9)):563-78 doi:10.1038/nrneph.2016.99.
PMID: 27452363
8
C3 glomerulonephritis secondary to mutations in factors H and I: rapid recurrence in deceased donor kidney transplant effectively treated with eculizumab.
Garg N, Zhang Y, Nicholson-Weller A, et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2018; (33(12)):2260-2265 doi:10.1093/ndt/gfx369.
PMID: 29370420
9
Rare complement factor I variants associated with reduced macular thickness and age-related macular degeneration in the UK Biobank.
Tzoumas N, Kavanagh D, Cordell HJ, et al.
Human molecular genetics 2022; (31(16)):2678-2692 doi:10.1093/hmg/ddac060.
PMID: 35285476
10
Evaluating a Causal Relationship between Complement Factor I Protein Level and Advanced Age-Related Macular Degeneration Using Mendelian Randomization.
Jones AV, MacGregor S, Han X, et al.
Ophthalmology science 2022; (2(2)) doi:10.1016/j.xops.2022.100146.
PMID: 35693873
11
Geographic Atrophy in Patients with Age-Related Macular Degeneration Is Associated with Rare Variants in Complement Factor H and Complement Factor I.
de Breuk A, de Jong S, Bakker B, et al.
Ophthalmology science 2026; (6(6)):101171 doi:10.1016/j.xops.2026.101171.
PMID: 42222588
12
Rare Dysfunctional Complement Factor I Genetic Variants and Progression to Advanced Age-Related Macular Degeneration.
Seddon JM, Rosner B, De D, et al.
Ophthalmology science 2023; (3(2)):100265 doi:10.1016/j.xops.2022.100265.
PMID: 36909148
13
Prevalence and phenotype associations of complement factor I mutations in geographic atrophy.
Khan AH, Sutton J, Cree AJ, et al.
Human mutation 2021; (42(9)):1139-1152 doi:10.1002/humu.24242.
PMID: 34153144
14
A Randomized Phase 2 Study of an Anti-Amyloid β Monoclonal Antibody in Geographic Atrophy Secondary to Age-Related Macular Degeneration.
Rosenfeld PJ, Berger B, Reichel E, et al.
Ophthalmology. Retina 2018; (2(10)):1028-1040 doi:10.1016/j.oret.2018.03.001.
PMID: 31047490
15
Cutaneous Vasculitis and Recurrent Infection Caused by Deficiency in Complement Factor I.
Nanthapisal S, Eleftheriou D, Gilmour K, et al.
Frontiers in immunology 2018; (9()):735 doi:10.3389/fimmu.2018.00735.
PMID: 29696024
16
Novel CFI mutation in a patient with leukocytoclastic vasculitis may redefine the clinical spectrum of Complement Factor I deficiency.
Bay JT, Katzenstein TL, Kofoed K, et al.
Clinical immunology (Orlando, Fla.) 2015; (160(2)):315-8.
PMID: 25988862
17
CNS Inflammation as the First Sign of Complement Factor I Deficiency: A Severe Myelitis Treated With Intense Immunotherapy and Eculizumab
Massey V, Nguyen CE, François T, et al.
Neurology(R) neuroimmunology & neuroinflammation 2024; (11(2)):e200191 doi:10.1212/NXI.0000000000200191.
PMID: 38134378
18
Complement factor I deficiency-associated neuroinflammatory disease among Old Order Amish.
Reid W, Baas L, Stiegler AL, et al.
The Journal of allergy and clinical immunology 2025; (156(3)):835-841 doi:10.1016/j.jaci.2025.06.021.
PMID: 40602690
19
Complete recovery after complement factor I deficiency associated fulminant acute hemorrhagic leukoencephalitis: a case report.
Szumutku F, Szabó L, Liptai Z, et al.
Frontiers in immunology 2025; (16()):1586288 doi:10.3389/fimmu.2025.1586288.
PMID: 40607425
20
Pearls & Oy-sters: Homozygous Complement Factor I Deficiency Presenting as Fulminant Relapsing Complement-Mediated CNS Vasculitis.
Levit E, Leon J, Lincoln MR
Neurology 2023; (101(2)):e220-e223 doi:10.1212/WNL.0000000000207079.
PMID: 36941072

This page is for informational purposes only and does not constitute medical advice about Complement Factor I deficiency. Your care team should determine kidney, eye, and other monitoring for you or your child.